OBX enters the final days of August with a striking divergence: the borrow market has gone from wide open to nearly locked shut in the span of two weeks, even as the stock itself tumbled 18% on the week.
The borrow story is the most dramatic development here. Availability collapsed from above 1,300% in mid-August — meaning the lending pool had vastly more shares than were being borrowed — to just 15% now. Every share in the lending pool is currently lent out. That shift happened fast: on August 13, availability was over 1,380%. By August 17, it was below 3%. The lending market has been at full utilization every day since. Cost to borrow rose 25% on the week to just under 8%, with a mid-month spike to 11% on August 5 suggesting the pool has been contested intermittently. Short sellers wanting new exposure face a genuinely tighter market than existed even two weeks ago, despite the stock being 18% lower on the week.
The short score softened meaningfully on Wednesday. It dropped from around 59 earlier in the week to 50 — a move worth watching given how abruptly availability tightened. The ORTEX short score had been climbing through mid-August, consistent with the borrow compression, but the drop mid-week suggests some of the short-side pressure may be unwinding even as availability remains low. The FINRA fortnightly print — the most recent official read — showed only 36,102 shares short as of August 14, the day availability was still at 37%. That figure almost certainly understates the current position given how sharply the lending market moved in the days after.
On the Street, analysts are freshly constructive. Both current ratings are initiations from this month. LifeSci Capital started coverage on August 18 with an Outperform and a $43 target. Piper Sandler launched on August 5 with Overweight and a $42 target. The consensus target of $42.50 is more than 2.5x the current price of $16.30. That gap is wide even by biotech standards — but these are fresh initiations on what was a micro-cap name before its extraordinary run, and the analysts are explicitly pricing in clinical progress rather than current fundamentals. The company's enterprise value is roughly $263 million, with no earnings multiples available. This is a binary clinical story priced accordingly.
The stock's weekly move — down 18% — stands out against most peers, which lost between 3% and 7% on the week. BNTC fell 7.5%, TSHA fell 5.3%, and ABEO slipped 2.8%. SMMT was the outlier, gaining 4.3% on the week. OBX's underperformance relative to that group suggests the selloff has a name-specific dimension — likely profit-taking after an extraordinary year-to-date run — rather than being purely a biotech sector move.
With no next earnings date in the system, and the most recent event on August 28 showing no price-reaction data yet attached, the near-term focus is on whether the borrow availability floor holds and whether the newly initiated analyst coverage draws additional institutional interest beyond the two holders currently on record.
See the live data behind this article on ORTEX.
Open OBX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
